

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

TIGIT

RRID:AB_2739254

Type: Antibody

Proper Citation

BD Biosciences Cat# 565474, RRID:AB_2739254

Antibody Information

URL: http://antibodyregistry.org/AB_2739254

Proper Citation: BD Biosciences Cat# 565474, RRID:AB_2739254

Target Antigen: TIGIT

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: TIGIT

Description: This monoclonal targets TIGIT

Target Organism: mouse

Clone ID: 1G9

Antibody ID: AB_2739254

Vendor: BD Biosciences

Catalog Number: 565474

Record Creation Time: 20231110T033520+0000

Record Last Update: 20260829T063632+0000

Ratings and Alerts

No rating or validation information has been found for TIGIT.

No alerts have been found for TIGIT.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Agesta A, et al. (2026) The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy. Immunity, 59(7), 1876.

Vitiello PP, et al. (2025) Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. Cancer cell, 43(7), 1296.

Burger ML, et al. (2021) Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell, 184(19), 4996.

Abd Hamid M, et al. (2020) Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses. Cancer immunology research, 8(2), 203.